<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360434</url>
  </required_header>
  <id_info>
    <org_study_id>NI006-101</org_study_id>
    <secondary_id>2019-001932-80</secondary_id>
    <nct_id>NCT04360434</nct_id>
  </id_info>
  <brief_title>First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy</brief_title>
  <official_title>A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Multicenter, Single and Multiple Ascending Dose Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy Followed by an Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurimmune AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurimmune AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1, randomized, placebo-controlled, double-blind, dose escalation trial combining
      single-ascending dose and multiple-ascending dose phases of NI006 or placebo, followed by an
      open-label extension phase in subjects with Amyloid Transthyretin Cardiomyopathy (ATTR-CM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 1, randomized, placebo-controlled, double-blind trial in subjects with Amyloid
      Transthyretin Cardiomyopathy (ATTR-CM) consists of single-ascending dose (SAD) and
      multiple-ascending dose (MAD) phases, followed by an open-label extension (OLE) phase.

      In the SAD phase subjects are randomized in a 4:2 ratio to receive a single infusion of NI006
      or placebo.

      Subjects completing the SAD phase will be enrolled in the MAD phase upon evaluation of all
      available safety data and receive a maximum of 3 additional infusions of NI006 or placebo
      every 28 days.

      Subjects completing the MAD phase will have the possibility to continue in an OLE phase with
      treatment up-titrations and switch from placebo to NI006 and receive up to 8 infusions of
      NI006 every 28 days.

      In the dose escalation about 30 to 36 subjects are planned to be enrolled in 5 to 6 ascending
      dose cohorts of 6 subjects each.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">August 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters, vital signs, electrocardiogram and echocardiogram</measure>
    <time_frame>4 months</time_frame>
    <description>Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters (hematology, clinical chemistry, immunology, urinalysis), vital signs, electrocardiogram and echocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters, vital signs, electrocardiogram and echocardiogram</measure>
    <time_frame>12 months</time_frame>
    <description>Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters (hematology, clinical chemistry, immunology, urinalysis), vital signs, electrocardiogram and echocardiogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NI006 pharmacokinetic profile and parameters - Cmax</measure>
    <time_frame>4 months</time_frame>
    <description>Maximum observed serum concentration (Cmax) of NI006</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NI006 pharmacokinetic profile and parameters - Tmax</measure>
    <time_frame>4 months</time_frame>
    <description>Time to maximum observed serum concentration (Tmax) of NI006</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NI006 pharmacokinetic profile and parameters - AUCinf</measure>
    <time_frame>1 month</time_frame>
    <description>Area under the serum concentration-time curve from zero to infinity (AUCinf) of NI006</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NI006 pharmacokinetic profile and parameters - CL</measure>
    <time_frame>4 months</time_frame>
    <description>Serum clearance (CL) of NI006</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NI006 pharmacokinetic profile and parameters - Vz</measure>
    <time_frame>4 months</time_frame>
    <description>NI006 apparent volume of distribution during terminal phase (Vz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NI006 pharmacokinetic profile and parameters - Vss</measure>
    <time_frame>4 months</time_frame>
    <description>NI006 apparent volume of distribution at steady state (Vss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NI006 pharmacokinetic profile and parameters - t½</measure>
    <time_frame>4 months</time_frame>
    <description>Terminal elimination half-life (t½) of NI006 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NI006 pharmacokinetic profile and parameters - AUCtau</measure>
    <time_frame>4 months</time_frame>
    <description>Area under the serum concentration-time curve from time zero to the end of the dosing interval after the first dose (AUCtau) of NI006</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NI006 pharmacokinetic profile and parameters - RaccCmax</measure>
    <time_frame>4 months</time_frame>
    <description>Accumulation ratio for maximum concentration (RaccCmax) of NI006 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NI006 pharmacokinetic profile and parameters - RaccAUC</measure>
    <time_frame>4 months</time_frame>
    <description>Accumulation ratio calculated from AUC (RaccAUC) of NI006 in serum</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory - Efficacy of multiple doses of NI006 on 6-Minute Walk Test (6-MWT)</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Changes in 6-MWT</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Efficacy of multiple doses of NI006 on patient questionnaire outcome</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Changes in patient questionnaire outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Efficacy of multiple doses of NI006 on amyloid load</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Changes in amyloid load assessed by cardiac imaging</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Efficacy of multiple doses of NI006 on cardiac biomarkers - NT-proBNP</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Changes in NT-proBNP concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Efficacy of multiple doses of NI006 on cardiac biomarkers - Troponin-T</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Changes in Troponin-T concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Immunogenicity of NI006</measure>
    <time_frame>4 and 12 months</time_frame>
    <description>Determination of anti-drug antibody response</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Amyloid Transthyretin Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>NI006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation in up to 6 dose cohorts. Subjects will be administered a single dose of NI006 in the SAD, multiple doses of NI006 in the MAD and OLE phases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be administered a single dose of placebo in the SAD phase and multiple doses of placebo in the MAD phase.
In the OLE phase, all subjects will be administered multiple doses of NI006.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NI006</intervention_name>
    <description>NI006 will be administered intravenously</description>
    <arm_group_label>NI006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age ≥18 years

          2. Confirmed diagnosis of ATTR-Cardiomyopathy

          3. Known genotype (wild-type or hereditary form)

          4. Chronic Heart Failure with LVEF ≥40%, LVWT ≥14 mm, NT-proBNP ≥ 600 pg/mL, 6-MWT ≥150
             meter, no hospitalizations for cardiac disease for at least 30 calendar days prior to
             screening

          5. Karnofsky Performance Status score ≥60%

        Key Exclusion Criteria:

          1. Amyloid light-chain amyloidosis or any other non ATTR amyloidosis

          2. New York Heart Association class IV

          3. NT-proBNP ≥6000 pg/mL

          4. Heart failure not predominantly caused by ATTR-Cardiomyopathy

          5. Any severe uncorrected valve disease

          6. Chronic liver disease with liver function test abnormalities

          7. Respiratory insufficiency requiring oxygen therapy

          8. Renal insufficiency

          9. Active malignancy with exception of: adequately treated basal cell carcinoma, squamous
             cell carcinoma of the skin, in situ cervical cancer, low risk prostate cancer with
             Gleason score &lt; 7 and prostate specific antigen &lt; 10 mg/mL, any other cancer from
             which the subject has been disease-free for ≥ 2 years

         10. Uncontrolled infection, HIV infection, seropositivity for HIV, hepatitis B and C,
             active hepatitis A

         11. Autoimmune disease requiring immunosuppressive/modulating treatment in the last 2
             years

         12. History of organ transplantation or ventricular assist device

         13. Polyneuropathy disability score &gt; IIIA

         14. Suspected or known drug or alcohol abuse, serious psychiatric or any other medical
             condition, which, in the opinion of the Investigator, makes the subject unsuitable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eva Herrmann-Keiner</last_name>
    <phone>+41 44 755 4622</phone>
    <email>eva.herrmann@neurimmune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jolanta Klovaite, MD, PhD</last_name>
    <phone>+41 44 755 4658</phone>
    <email>jolanta.klovaite@neurimmune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ATTR</keyword>
  <keyword>Transthyretin</keyword>
  <keyword>Amyloidosis</keyword>
  <keyword>Cardiomyopathy</keyword>
  <keyword>ATTR-CM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

